A Randomized, Phase II, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating The Efficacy And Safety Of Onartuzumab (MetMAb) In Combination With 5-Fluorouracil, Folinic Acid, And Oxaliplatin (mFOLFOX6) In Patients With Metastatic HER2-Negative Gastroesophageal Cancer

Trial Profile

A Randomized, Phase II, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating The Efficacy And Safety Of Onartuzumab (MetMAb) In Combination With 5-Fluorouracil, Folinic Acid, And Oxaliplatin (mFOLFOX6) In Patients With Metastatic HER2-Negative Gastroesophageal Cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 10 Aug 2016

At a glance

  • Drugs Onartuzumab (Primary) ; Fluorouracil; Folinic acid; Levofolinic acid; Oxaliplatin
  • Indications Adenocarcinoma; Gastric cancer; Gastrointestinal cancer; Oesophageal cancer
  • Focus Therapeutic Use
  • Sponsors Roche
  • Most Recent Events

    • 03 Nov 2014 Status changed from active, no longer recruiting to completed, as per ClinicalTrials.gov record.
    • 03 Feb 2014 Planned End Date changed from 1 Aug 2014 to 1 July 2014 as per ClinicalTrials.gov record.
    • 13 Jan 2014 Status changed from recruiting to active, no longer recruiting as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top